HKSE - Delayed Quote HKD

Shanghai Henlius Biotech, Inc. (2696.HK)

Compare
23.900 +0.050 (+0.21%)
At close: 4:08:08 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
5,394,909.000
5,394,909.000
3,214,730.000
1,682,472.000
587,586.000
Cost of Revenue
1,476,112.000
1,476,112.000
844,621.000
522,748.000
182,119.000
Gross Profit
3,918,797.000
3,918,797.000
2,370,109.000
1,159,724.000
405,467.000
Operating Expense
3,196,999.000
3,196,999.000
2,728,801.000
1,782,901.000
1,295,039.000
Operating Income
721,798.000
721,798.000
-358,692.000
-623,177.000
-889,572.000
Net Non Operating Interest Income Expense
-102,393.000
-102,393.000
-102,101.000
-82,134.000
-36,301.000
Pretax Income
569,578.000
569,578.000
-693,887.000
-956,739.000
-993,541.000
Tax Provision
23,559.000
23,559.000
1,372.000
27,313.000
--
Net Income Common Stockholders
546,019.000
546,019.000
-695,259.000
-984,052.000
-993,541.000
Diluted NI Available to Com Stockholders
546,019.000
546,019.000
-695,259.000
-984,052.000
-993,541.000
Basic EPS
1.01
1.01
-1.28
-1.83
-1.88
Diluted EPS
1.00
1.00
-1.28
-1.83
-1.88
Basic Average Shares
543,299.247
543,299.247
542,021.455
538,836.373
529,574.066
Diluted Average Shares
543,373.104
543,373.104
542,021.455
538,836.373
529,574.066
Total Expenses
4,673,111.000
4,673,111.000
3,573,422.000
2,305,649.000
1,477,158.000
Net Income from Continuing & Discontinued Operation
546,019.000
546,019.000
-695,259.000
-984,052.000
-993,541.000
Normalized Income
575,046.553
575,046.553
-544,665.750
-983,921.500
-993,555.000
Interest Income
8,146.000
8,146.000
3,571.000
2,686.000
7,404.000
Interest Expense
110,539.000
110,539.000
105,672.000
84,820.000
43,705.000
Net Interest Income
-102,393.000
-102,393.000
-102,101.000
-82,134.000
-36,301.000
EBIT
680,117.000
680,117.000
-588,215.000
-871,919.000
-949,836.000
EBITDA
1,039,350.000
1,039,350.000
-310,612.000
-671,743.000
-814,060.000
Reconciled Cost of Revenue
1,476,112.000
1,476,112.000
844,621.000
522,748.000
182,119.000
Reconciled Depreciation
359,233.000
359,233.000
277,603.000
200,176.000
135,776.000
Net Income from Continuing Operation Net Minority Interest
546,019.000
546,019.000
-695,259.000
-984,052.000
-993,541.000
Total Unusual Items Excluding Goodwill
-30,280.000
-30,280.000
-200,791.000
-174.000
14.000
Total Unusual Items
-30,280.000
-30,280.000
-200,791.000
-174.000
14.000
Normalized EBITDA
1,069,630.000
1,069,630.000
-109,821.000
-671,569.000
-814,074.000
Tax Rate for Calcs
0.000
0.000
0.000
0.000
--
Tax Effect of Unusual Items
-1,252.447
-1,252.447
-50,197.750
-43.500
--
12/31/2020 - 9/25/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

2616.HK CStone Pharmaceuticals
2.300
-1.71%
 
EMBT Ember Therapeutics, Inc.
0.0001
0.00%
 
INNMF Amplia Therapeutics Limited
0.0550
-21.43%
 
1228.HK CANBRIDGE-B
0.147
-3.92%
 
2511.HK HighTide Therapeutics, Inc.
1.140
+6.54%
 
2157.HK Lepu Biopharma Co., Ltd.
2.980
-5.10%
 
3759.HK Pharmaron Beijing Co., Ltd.
13.720
-0.15%
 
1952.HK Everest Medicines Limited
46.500
-0.75%
 
9688.HK Zai Lab Limited
20.600
+1.48%
 
EFTR eFFECTOR Therapeutics, Inc.
0.0002
0.00%